Ensysce Biosciences Invited to Upcoming Scientific and Industry Events

Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Ensysce Biosciences, a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, announced that members of its executive management team have been invited to participate in upcoming scientific and industry events focused on next-generation pain therapeutics, substance use disorder research, and commercial best practice.

Why it matters

Ensysce's participation in these events provides an opportunity to engage with the clinical, scientific, and industry communities and to highlight the company's differentiated approach to developing innovative therapeutics with the potential to reduce abuse and overdose risk.

The details

The events Ensysce's leadership team will participate in include the U.S. Association for the Study of Pain (USASP) Annual Scientific Meeting, the First-ever European Pain Therapeutics Summit, the Commercial Excellence and AI – Immersion Lab, and the College on Problems of Drug Dependence (CPDD) 88th Annual Meeting. At these events, Ensysce will provide updates on its technology platforms, highlight their novelty, and discuss the development strategy for both PF614 and PF614-MPAR.

  • The U.S. Association for the Study of Pain (USASP) Annual Scientific Meeting will take place on March 23-26, 2026 in Philadelphia, PA.
  • The First-ever European Pain Therapeutics Summit will be held on May 7-8, 2026 in Amsterdam, Netherlands.
  • The Commercial Excellence and AI – Immersion Lab will take place on June 3-4, 2026 in Philadelphia, PA.
  • The College on Problems of Drug Dependence (CPDD) 88th Annual Meeting will be held on June 13-17, 2026 in Portland, OR.

The players

Dr. Lynn Kirkpatrick

Chief Executive Officer of Ensysce Biosciences.

Dr. William Schmidt

Member of Ensysce Biosciences' executive management team.

Mr. Geoff Birkett

Member of Ensysce Biosciences' executive management team.

Ensysce Biosciences, Inc.

A clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose.

Got photos? Submit your photos here. ›

What they’re saying

“These engagements provide important opportunities to engage with the clinical, scientific, and industry communities and to highlight Ensysce's differentiated approach to developing innovative therapeutics with the potential to reduce abuse and overdose risk.”

— Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences (Ensysce Biosciences)

The takeaway

Ensysce Biosciences' participation in these upcoming scientific and industry events demonstrates the company's commitment to advancing safer, evidence-based innovation in pain therapeutics and addressing the critical issue of opioid abuse and overdose.